Living without DAT: Loss and compensation of the dopamine transporter gene in sauropsids (birds and reptiles)

P. V. Lovell1, B. Kasimi1,2, J. Carleton2–†, T. A. Velho1,‡ & C. V. Mello1

The dopamine transporter (DAT) is a major regulator of synaptic dopamine (DA) availability. It plays key roles in motor control and motor learning, memory formation, and reward-seeking behavior, is a major target of cocaine and methamphetamine, and has been assumed to be conserved among vertebrates. We have found, however, that birds, crocodiles, and lizards lack the DAT gene. We also found that the unprecedented loss of this important gene is compensated for by the expression of the noradrenaline transporter (NAT) gene, and not the serotonin transporter genes, in dopaminergic cells, which explains the peculiar pharmacology of the DA reuptake activity previously noted in bird striatum. This unexpected pattern contrasts with that of ancestral vertebrates (e.g. fish) and mammals, where the NAT gene is selectively expressed in noradrenergic cells. DA circuits in birds/reptiles and mammals thus operate with an analogous reuptake mechanism exerted by different genes, bringing new insights into gene expression regulation in dopaminergic cells and the evolution of a key molecular player in reward and addiction pathways.

Dopamine (DA) is a prominent modulatory neurotransmitter. In all vertebrates, including fish, amphibians, mammals, reptiles, and birds, and it is involved in a broad range of functions, including motor control and motor learning, memory formation, and reward-seeking behavior, among others 1–5. Thus it is not surprising that several properties of dopaminergic systems are shared across vertebrates, including DA biosynthetic and catalytic pathways, many aspects of the organization of DA projection systems, physiological properties of DA neurons, and several aspects of the brain distribution of DA receptors 6–12 (see also reviews in 13). In mammals, synaptic availability of DA is regulated by the kinetics of DA release and, more importantly, through rapid re-uptake by a plasma membrane bound DA transporter (DAT; a.k.a. SLC6A3). Consistent with this prominent physiological role, the DAT gene has been associated with neurological disorders, such as dystonia/parkinsonism14, and psychiatric disorders such as attention deficit hyperactivity disorder, bipolar disorder, clinical depression, and drug addiction15,16. Similar to mammals, there is evidence that synaptic DA re-uptake also operates in birds and reptiles, playing important roles in behaviors such as communication through learned vocalizations in songbirds, control of male sexual behavior in quail17,18 and visual courtship displays in whiptail lizards19–21. The general assumption has thus been that synaptic DA re-uptake is conserved across vertebrates22,23, however the genetic basis of DA transport systems in non-mammalian amniotes is unknown.

To address this gap, we set out to investigate the evolution and brain expression of the DAT gene in sauropsids (birds and reptiles). We focused on the substantia nigra (SN) and ventral tegmental area

1Department of Behavioral Neuroscience; Oregon Health & Science University; Portland, OR 97239-3098; USA.
2Department of Biology; Portland State University; Portland, OR 97207-0751; USA. †Present address: Biology Program; University of Utah; Salt Lake City, UT 84112-9057; USA. ‡Present address: Institute; Federal University of Rio Grande do Norte, Natal, RN 59056-450; Brazil. Correspondence and requests for materials should be addressed to C.V.M. (melloc@ohsu.edu)
(VTA), which are the primary sources of DA projections to the striatum and limbic structures, and are particularly prominent in higher vertebrates like mammals, reptiles and birds (see reviews in 24). DA cells in both the SN and VTA are readily identifiable through expression of the biosynthetic enzymes dopamine decarboxylase (DDC) and tyrosine hydroxylase (TH). Furthermore, these cells in mammals express DAT, which regulates the synaptic availability of DA and limits its actions on post-synaptic receptors within mesostriatal and mesocorticolimbic DA projections.

Using a combination of sequence alignments and synteny analysis, we discovered that the DAT gene is absent in sauropsids, raising questions concerning how birds and reptiles regulate synaptic DA levels, and whether this basic feature of DA projection systems might differ from mammals. Using in situ hybridization, we obtained unambiguous evidence that the noradrenergic transporter (NAT; a.k.a. SLC6A2), which in mammals is a marker of noradrenergic (NA) cells, is expressed in the SN and VTA of birds (Zebra finch and lizards (Green anole), where it co-localizes with DA cell markers. This pattern is in sharp contrast to mammals, where DAT and NAT segregate to distinct brain nuclei and cell types, and fish, where we found no co-expression of NAT and DAT. We suggest that this modified NAT expression functionally compensates for loss of DAT in birds and reptiles, a possibility that explains previous pharmacological data indicating that avian striatal DA transport has features consistent with NAT of mammals25,26. Thus, DA transport systems have distinct genetic bases in birds/lizards compared to mammals (usage of NAT as opposed to DAT). These findings yield new insights into the transcriptional regulation of DA cells and, more generally, into the evolution of DA transporter mechanisms in amniotes.

Materials & Methods
Phylogenomic Analysis of the DAT Gene.

To examine the presence/absence of the DAT gene across the vertebrate phylogeny we first consulted Ensembl (e75) and NCBI’s Refseq collections to identify any entries in the genomes of mammals (i.e. opossum, BOADO5; platypus, OANA5; mouse, GRCi38; human, GRCh37), birds (i.e. chicken, Galgal4; zebra finch, taeGut3.2.4; turkey, UMD2), crocodiles (i.e. American alligator, allMis0.2; Chinese alligator; ASM45574v1), reptiles (Anole lizard, AnoCar2.0; Chinese softshell turtle, PelSin_1.0), amphibians (xenopus; JGI_4.2), and teleosts (i.e. tilapia, OreI1.0; fugu, FUGU4; zebrafish, Zv9) currently annotated as either SLC6A3 or DAT. We did not find any such entries in any sauropsid (i.e. reptile or avian) genomes. However, to be certain that the DAT gene was not present but rather mis-annotated, or “hiding” in an unassembled region of the genome, we next conducted an exhaustive series of BLAT alignments against well-assembled high-coverage avian genomes (above avian genomes plus medium ground finch, GeoFor_1.0; and budgerigar, melUnd1), crocodile (American alligator, AllMis0.2), and reptile genomes (above reptile genomes plus painted turtle, chrPic1) using both nucleotide and protein coding sequences from DAT orthologs in zebrafish (ENSARG00000004219), frog (ENSTXGTG00000001728), mouse (ENSMUSG00000021609), and humans (ENSG00000142319). BLAT searches were conducted using parameters that maximized sensitivity, which increased the number of false positives, but allowed us to verify that the DAT gene was not present. We also performed additional BLAT and BLASTn searches against an improved gap-filled zebrafish genome (Mello and Warren, unpublished data) assembled from additional Illumina sequencing reads, as well as the largest available chicken EST collections (e.g. BBSRC give details here, Univ. Delaware Chick EST). We also conducted a series of BLASTn and BLASTp searches (using Block Substitution Matrix 45 for highly divergent sequences; word size 11 for DNA, 3 for protein) of NCBI’s nucleotide and protein collections. Finally, we conducted comprehensive tBLASTn searches21 against unassembled Whole Genome Shotgun (WGS) sequences derived from 45 additional avian genomes (N = 45; Table S1 in 27; datasets available at http://ggdb.org/dataset/view/id/101000/files_page/2), as well as several others that have been made publicly available by various research groups (N = 12; Puerto Rican parrot, Amazona vittata; Golden Eagle, Aquila chrysaetos; Scarlet macaw, Ara macao; Northern bobwhite, Colinus virginianus; Hooded crow, Corvus cornix; Japanese quail, Coturnix japonica; Saker falcon, Falco cherrug; Collared flycatcher, Ficedula albicollis; Black grouse, Lyurus tetrix; Tibetan tit, Pseudopodoces humilis; Canary, Serinus canaria; White-throated sparrow Zonotrichia albicollis). For each of these analyses, we manually verified any significant hits by syntenic analysis whenever possible. We note that in all cases, the highest-scoring hits were to closely related monooamine transporter genes (i.e. SLC6A2, a.k.a. NAT, or SLC6A4, a.k.a. SERT). We note that fish, lizards, and birds possess an additional paralog of SLC6A4 (a.k.a. SLC6A4B) that is absent in mammals, including humans (See Results and for details). We also note that for nearly all of the species examined we were able to directly verify the presence of the chromosomes region that would be expected to contain the DAT gene by conducting a comparative analysis of synteny.

Of note, our search, alignment, and annotation efforts were required to establish the DAT gene loss in sauropsids, and we did not simply rely on the annotations provided by Ensembl. In our experience, Ensembl is an incomplete prediction database. Several genes that are known to exist in a given genome are often incompletely predicted, or not predicted at all. Furthermore, Ensembl contains genes that have been misannotated. As previous studies from our group have revealed28–30, cases of gene duplications and/or gene losses can only be conclusively established by utilizing direct searches with appropriate alignment tools such as BLAT and BLAST against the appropriate genomes, and by direct examination of mRNA/EST databases.

All sequence analyses were performed using the eBioX (1.5.1) suite of analysis tools. Multiple alignments of NAT protein sequences were estimated using the ClustalW alignment algorithm with standard
parameters\textsuperscript{31}, and sequence identities were calculated using SIAS (http://imed.med.ucm.es/Tools/sias.html; gaps were not taken into account).

**Animal preparation.** We used a total of 6 adult male zebra finches (\textit{Taeniopygia guttata}), 4 adult sex-undetermined green anoles (\textit{Anolis carolinensis}), and 3 adult male dominant Burtoni cichlids (\textit{Astatotilapia burtoni}) that were respectively obtained from our own breeding colony, purchased from local breeders, or made available to us by the Renn lab (Reed College). For zebra finches, individuals were first isolated overnight (12:12-hour light-dark cycle) in custom-built acoustic isolation chambers to reduce non-specific auditory stimulation. On the following morning (~9:00 AM), birds were monitored for at least 1 hour, and confirmed to be non-singing. Regardless of species, animals were sacrificed by decapitation, their brains were removed and bisected to reproduce an approximation of the “Frankfurt” frontal plane\textsuperscript{32}, and frozen in O.C.T. compound (Tissue-Tek). Brains were sectioned on a cryostat (10μm) and prepared for \textit{in situ} hybridization as described in\textsuperscript{33}. Animal protocols were approved by OHSU’s IACUC committee and are in accordance with NIH guidelines.

**Clone Selection and \textit{in situ} Hybridization.** Clones corresponding to the Zebra Finch noradrenaline transporter (NAT; FE735918) and dopa decarboxylase (DDC; DV957042) genes were obtained from the ESTIMA Zebra Finch brain cDNA collection\textsuperscript{44}. For these clones, plasmid DNA was restriction enzyme digested (BSSHII; New England Biolabs) to release the template insert, and then purified with a PureLink PCR purification kit (Life technologies). To obtain Zebra Finch dopamine beta-hydroxylase (DBH), we designed primers (Primers: DBHexon1-10, 5'GCCAGGTGCCGGGTGCCATCC-3'; DBHexon1-313, 5'GTCGCGCATCCGGAAGG-3') to PCR amplify the first exon of the DBH gene from genomic DNA derived from Zebra Finch muscle genomic DNA. Gradient PCR (Ta = 42°C to 62°C; 30 rounds of amplification) yielded a ~313 bp product, which was then gel purified, and cloned into a pBluescript-II (+) vector (Stratagene). The partial mRNA sequence for this clone has been submitted to GenBank (Accession Number: KP299259).

Clones for the Nile Tilapia (\textit{Oreochromis niloticus}) dopamine transporter (DAT; GR671131) and for NAT (GR666231) were obtained from the Cichlid Genome Consortium (http://cichlid.umd.edu/cichlid-labs/kocherlab/bouillabase.html) and the Kocher lab\textsuperscript{35}. Clones for the green anole (\textit{Anolis carolinensis}) NAT (FG784332) and tyrosine hydroxylase (TH; FG660029) were obtained from the Colbourne lab and the Indiana University Center for Genomics and Informatics\textsuperscript{36}. Because Nile Tilapia and Green Anole cDNAs were cloned into sequencing vectors that lacked RNA polymerase promoter sites for riboprobe synthesis, we PCR amplified these cDNA using pairs of gene specific primers that included an additional 5' extension corresponding to the sequence for T3 (antisense strand) or T7 (sense strand) RNA polymerase promoter (Ta = 60°C, 35 rounds of amplification). Resulting DNA fragments were purified using a PureLink PCR clean-up kit (Life Technologies) and used as template for \textit{in vitro} transcription of cRNA probes (see Supplementary Table 1 for primer and template details). For ESTIMA clones and PCR-derived templates, sense and antisense strand probes were synthesized at 37°C for 3 hours using the appropriate T3 or T7 RNA polymerase (Promega Inc., Madison, WI), with either digoxigenin (DIG)-UTP or fluorescein-UTP in the nucleotide label mix. Resulting probes were purified by Sephadex G-50 columns\textsuperscript{37}.

All of the methods for performing single and double \textit{in situ} hybridization were essentially as described in\textsuperscript{30,33,37}. After post-fixation and dehydration sections were hybridized with a solution (16μl per section) containing 50% deionized formamide, 2 × SSPE, 1 μg/μl tRNA, 1 μg/μl BSA, 1 μg/μl poly-A in DEPC-treated water, and 2 μl of DIG- and/or fluorescein-labeled riboprobe. Slides were coverslipped, sealed by immersion in mineral oil, and incubated overnight at 63–65°C. The following day sections were rinsed in chloroform, de-coverslipped in 2x SSPE, and washed by incubating serially for 1 hr at RT in 2 × SSPE, 1 hr at 63–65°C in 2 × SSPE containing 50% formamide, and twice in 0.1 × SSPE for 30 min at 63–65°C.

For single-labeling \textit{in situ} hybridization, sections were blocked for 30 min at RT in TNB buffer (100 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 μg/μl bovine serum albumin, 0.3% Triton X-100), incubated for 2 hr in TNB with an alkaline phosphatase conjugated anti-DIG antibody (anti-DIG-AP; 1:600 dil., Roche Applied Science, Mannheim, Germany), washed briefly in TNN buffer (in mM; 100 Tris-HCl pH 9.5, 150 NaCl, 5 MgCl\textsubscript{2}), and incubated for 1–3 days in a ready-to-use tris-buffered solution containing the alkaline phosphatase substrates Nitro-Blue Tetrazolium Chloride (NBT; 0.42 g/L) and 5-Bromo-4-Chloro-3-Indolyl-phosphate p-Toluidine Salt (BCIP/NBT; 0.21 g/L; Substrate Solution NEL937, Perkin-Elmer, Waltham, MA). Developed slides were briefly rinsed in distilled water to remove salts, fixed in 3% buffered paraformaldehyde solution, rinsed in distilled water, and coverslipped with aquamount (Lerner Laboratories, Pittsburg, PA).

For double-labeling fluorescent \textit{in situ} hybridization, we used various combinations of DIG- and fluorescein-labeled riboprobes. All of the hybridizations, washes, and section blocking were essentially as described above for single labeling \textit{in situ}. DIG-labeled probes were developed first by incubating sections overnight at 4°C in TNB with a horseradish peroxidase conjugated anti-DIG antibody (anti-DIG-HRP; 1:800 dil.; Roche Applied Science). Sections were then washed 3 times for 5 min at RT in TNT (100 mM Tris-HCl pH9.5, 150 mM NaCl, 0.3% Triton X-100), and incubated at RT for 1 hr with Alexa 488-conjugated-tyramide in amplification buffer (1:100 dil.; Invitrogen, Carlsbad, CA) according to the
manufacturer's recommended protocol. Sections were then washed 3 times for 5 min in TNT, and incubated for 20 min at RT in TNT plus 0.2% HCl to inactive the anti-DIG-HRP, followed by three washes for 5 min each in TNT. To visualize the fluorescein-labeled probe, sections were incubated for 2 hr in a solution of TNB with an HRP-conjugated anti-fluorescein antibody (1:500 dil., Roche Applied Science), washed 3 times for 5 min in TNT, and incubated at RT for 1 hr with Alexa 568-conjugated-tyramide in amplification buffer. Finally, sections were washed in TNT, counterstained with propidium iodide (0.1 μg/mL in TNT), and coveredslipped with aquamount. For each set of double-labeling in situ we included negative controls slides that were incubated without one or the other primary antisera to confirm labeling specificity and to verify HRP inactivation. We also developed in parallel a set of single labeling in situ for the DIG- and fluorescein-labeled riboprobes to detect verify detection sensitivity.

To address the issue of probe specificity, all clones utilized for in situ hybridization were examined by BLAT alignments to the corresponding genomes to verify that they specifically aligned to the expected loci, and lacked significant alignments to other loci. Furthermore, controls using sense strand probes or omitting riboprobes altogether were routinely incorporated to the hybridizations, and yielded no detectable signals.

**Image Acquisition and Figure Preparation.** Images of non-fluorescent in situ hybridization were acquired using a high-resolution digital slide-scanning system (Olympus Nanozoomer HT2). Additional photomicrographs were acquired with bright-field, or fluorescence optics using a digital camera (DVC co., Austin, TX) coupled to a Nikon E600 microscope. Drawings of transverse mouse brain sections were drawn based on Nissl series images available at the Allen Mouse Brain Atlas; available from: http://mouse.brain-map.org/. Photomicrographs showing the expression of NAT, DCC, and DBH in the mouse brain were obtained from the Allen Mouse Brain Atlas [Internet]; available from: http://mouse.brain-map.org ©2014 Allen Institute for Brain Science)38. We based our identification of catecholaminergic cell groups on brain atlases for zebra finch32,39, teleosts8,9,40, and lizard12, as well as reviews in13. Photoshop-CS5 (Adobe Systems Inc., San Jose, CA) was used to adjust photomicrographs. Specifically, we used the levels function to adjust the contrast and brightness of gray scale and color images. Color balancing was performed across sections so that background levels were similar. Figures were prepared in Illustrator-CS6 (Adobe Systems Inc.). BoxShade (http://www.ch.embnet.org/software/BOX_doc.html) was used to graphically present protein sequence multi-alignments and shade conserved residues.

**NAT and DAT Comparative Promoter Analysis.** To determine if the promoters of sauropsid NAT genes might contain transcription regulatory elements that are generally present in mammalian DATs, but not in NATs, we conducted a comprehensive comparative analysis of the NAT (and DAT) promoters in avian (i.e. chicken, zebra finch, turkey, and budgerigar) and mammalian (i.e. platypus, opossum, mouse, and rat) species. We first identified putative general promoter regions by determining a putative transcription start site (TSS) based on the alignments of same species ESTs, mRNAs, and RefSeq gene predictions. We next extracted the genomic sequence for a region ~2.5 kb upstream of the putative TSS; inclusion of sequences further upstream in our analysis was not feasible as there were either highly divergent or missing due to genomic gaps in several species. In some cases we were able to refine, or computationally validate the location of the TSS by scanning each promoter region with algorithms available through Softberry (http://linux1.softberry.com/berry.phtml) that predict TSSs based on the position of TATA or non-TATA promoter sequences (FPRM41), or the location of CpG-rich islands (CpGFinder). Next, we used the ‘SCAN’ algorithm available at JASPAR (http://jaspar.genereg.net42) to identify the positions of putative vertebrate transcription factor binding sites (TFBS43). We scanned each promoter sequence with the complete set of vertebrate core TFBS position weight matrix models that are available at JASPAR (http://jaspar.binf.ku.dk/cgi-bin/jaspar_db.pl?rm=/browse&db=core&tax_group=vertebrates) using conservative thresholding (i.e. relative profile score threshold >90%). For each lineage (i.e. avian or mammalian), and each gene (i.e. NAT or DAT), we next aligned sets of promoters according to the location of their TSS, and searched for the presence of conserved TFBSs within a series of consecutive ~500 bp segments starting at the TSS. For instance, starting with the first segment of the Zebra finch NAT promoter (bp 0 to −500) we first identified any TFBSs that were also present within the same segment in the budgerigar, chicken, and turkey NAT orthologs; we next sequentially identified the elements present in each of the other four 500 bp segments, up to position −2.5 kb from the TSS. We applied an identical analysis to the set of mammalian NAT and DAT promoters, using mouse NAT and DAT promoters as a starting point for each comparison, which included mouse, rat, opossum, and platypus (not included for DAT due to genomic gaps). All non-conserved TFBSs (i.e. not present in all species examined within each lineage) were removed from the analysis. Finally, we compared the composition of conserved TFBS in the avian NAT promoters (using the position of each TFBS in Zebra finch NAT) with the compositions of the conserved TFBS in the mammalian NAT and DAT promoters, and identified any TFBSs that were shared between the consensus avian NAT with the consensus mammalian NAT or with the consensus mammalian DAT promoters. We noticed that there is a highly conserved ARNT element in the proximal region of all consensus promoters and used this site to align the sequences presented; all other shared elements and the putative TSSs are mapped with reference to that element (i.e. position 0).
Results

The dopamine transporter (DAT) gene is missing in sauropsids. To determine whether the molecular determinants of DA transport in the vertebrate lineage that contains birds and reptiles (i.e. sauropsids) are as in mammals, we first searched the genomes of birds for the DAT gene. We note that in mammals, the DAT gene is situated within a highly conserved chromosomal region, immediately flanked by CLPTM1L and LPCAT1 (Fig. 1a). To our surprise, we found no evidence of the DAT gene in this location in chicken, (Fig. 1b), the best assembled, highest coverage sauropsid genome. Of note, the corresponding region in chicken (~12 kb), contains no gaps and has been assembled from high quality reads (Supplementary Fig. 1), thus the absence of the DAT gene is not due to low sequence coverage or assembly issues. Absence of the DAT gene in birds was further confirmed by syntenic analysis and exhaustive BLAT and mega-BLASTn searches of other high-coverage well assembled and annotated avian genomes (zebra finch and budgerigar; Fig. 1c), searches of avian expression databases (e.g. mRNA, EST, and RefSeq databases), as well as mega-BLASTn searches of the whole genome shotgun sequences for a large collection of additional avian species representing the majority of branches of the avian phylogenetic tree; n = 57; see Methods for details).

To determine the phylogenetic origin of the DAT gene loss in vertebrates, we next performed systematic searches and synteny analysis of the DAT gene in the genomes of representative non-avian sauropsids (American alligator, green anole, painted turtle) available in NCBI. However, we found no traces of the DAT gene in these species, neither at the same syntenic position as in mammals (Fig. 1d), nor in any other region of their genomes. We next investigated non-sauropsid vertebrates and verified the presence of DAT in fish, amphibians and non-eutherian mammals, including platypus and opossum (Fig. 1e). These findings point to a DAT loss that most likely occurred in an ancestral sauropsid (Fig. 1f).

Modified NAT expression compensates for the DAT loss in birds and lizard. It is possible that the DAT gene loss might be compensated by the modified expression of another monoamine transporter. To test this hypothesis, we used locus specific molecular probes and in situ hybridization to map the brain distributions of NAT and SERT along with markers of serotonergic (i.e. tryptophan hydroxylase, TPH2), catecholaminergic (i.e. dopa decarboxylase, DDC, or tyrosine hydroxylase, TH),
and noradrenergic (i.e. dopamine β-hydroxylase, DBH) cell groups in a representative avian species (i.e. zebra finch). As in mammals, SERT was expressed in serotonergic nuclei of the raphe complex, but not in the major midbrain dopaminergic nuclei VTA and SN (not shown). Also as expected, NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2a, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT expression is also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in dopaminergic nuclei VTA and SN (not shown). Also as expected, NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2a, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right). This finch NAT pattern is in sharp contrast to mammals, where NAT was expressed in noradrenergic (NA) nuclei, overlapping with the distribution of DBH (LoC shown in Fig. 2b, top row). Strikingly, however, NAT was also strongly expressed in the dopaminergic nuclei of the midbrain tegmentum, as demonstrated by its overlapping distribution with the catecholaminergic marker DDC (for SN, see Fig. 2a, top row, left and middle panels; for VTA, see Supplementary Fig. 5, top row, left and middle panels). Importantly, these dopaminergic nuclei do not contain NA cells, as confirmed here based on the lack of expression of DBH (Fig. 2a, top row right, and Supplementary Fig. 3, top row right).
Importantly, the SN and VTA in lizard are known to lack noradrenergic cells, based on the absence of immunolabeled somata for noradrenergic markers. Combined, our results indicate that the expression of NAT in both DA and NA cells is a general trait of sauropsids.

Expression of NAT and DAT are segregated in fish. Since fish represent a more basal vertebrate lineage that has both NAT and DAT, we next examined the brain of a representative teleost (i.e. Burtoni cichlid) to determine if the distribution of NAT in fish is comparable to that observed in sauropsids or in mammals. We found that the nucleus of the posterior tuberculum, the teleost equivalent of striatal-projecting dopaminergic cells in VTA/SN, was entirely devoid of NAT expression (Fig. 3b, left panel), although as expected neurons within this nucleus were well labeled by DAT (Fig. 3b, inset), consistent with their DA identity. Also as expected, NAT was strongly expressed in cells within the LoC (Fig. 3b, right panel), consistent with their NA identity, however no DAT expression was found in this nucleus. This pattern in teleosts is consistent with that seen in mammals, where the expression of NAT and DAT is segregated and NAT is not expressed in the SN/VTA, as well as previous evidence of lack of NAT expression in DA cells in medaka. Together, these results indicate that the segregation of DAT with DA cells, and NAT with NA cells is a trait conserved in fish and mammals that was altered in sauropsids, in concert with the loss of the DAT gene.

Comparative analysis of the NAT and DAT promoters. In an effort to identify regulatory elements that might be involved in the distinct expression of avian NAT in dopaminergic cells, we performed a comparative analysis of cis-regulatory elements in the promoters of avian NAT, and mammalian NAT and DAT. We specifically searched for conserved transcription factor binding sites based on JASPAR position-weight matrices located within 2,500 bp immediately upstream of the transcription start site of the NAT gene in avian species, and then assessed whether the same conserved elements were also conserved in the promoters of mammalian NAT and/or DAT (see Methods for details).
hypothesis was that despite an overall greater similarity between avian and mammalian NAT genes, the avian NAT would share some specific elements with mammalian DAT that are absent in mammalian NAT. Such elements, if present, might contribute to NAT expression in DA cells and thus constitute important candidates for mechanistic studies of gene expression regulation in DA cells. As expected, we found that the avian NAT promoter region shares a large number of conserved elements with mammalian NAT (Fig. 4, shared elements indicated by black lines) that were predictably absent in the mammalian DAT, including the presence of a core proximal homeodomain-binding motif that is known to confer cell-type specific expression to human NAT through interactions with the transcription factors HOXA5 and PHOX2A (Fig. 4, indicated by black arrow). However, we also found that avian NAT and mammalian DAT, but not mammalian NAT, share the presence of binding sites within similar regions for NFATC2, MZF1, and ZNF354C, as well as for FOXC1 (Fig. 4; red arrows and red lines). Thus, some specific elements that are conserved in mammalian DAT promoters are also present and conserved in avian NAT, representing candidate elements that may relate to expression in DA cells.

Discussion
We present conclusive evidence that the DAT gene is missing in sauropsids. Thus, a central component of the dopaminergic system that has traditionally been viewed as being highly conserved among vertebrates is actually absent in a major vertebrate lineage. Furthermore, we have established that in organisms that lack DAT, the NAT gene is expressed in DA cells. This expression pattern is in stark contrast with that observed in mammals, and provides a likely mechanism of compensation for the DAT gene loss. Importantly, we provide evidence that it is the sauropsid NAT ortholog that is expressed in DA cells, not a close paralog of the DAT or NAT genes, for which there is presently no evidence in sauropsids or in any other vertebrate genomes analyzed to date.

The loss of the DAT gene was a major surprise, since most features of the DA system are largely conserved across vertebrate taxa. DA transport activity, in particular, plays a key role in limiting synaptic DA availability (Fig. 5a), thus exerting strong modulatory roles over a wide range of functions, including...
motor control and reward mechanisms. As such, it has been largely assumed that the DAT gene must also be present in organisms like birds and lizards. Indeed, previous experimental evidence detected the presence of DA re-uptake activity in the mesostriatal system of the zebra finch, in terminals from dopaminergic projections from the SN and VTA to striatal song nucleus area X, suggesting that the expression of the DAT gene in SN/VTA was also conserved in sauropsids. In retrospect, however, some important pharmacological properties of the DA re-uptake activity detected in finch striatum notably differ from those in mammals. For instance, it was shown to be sensitive to a DA blocker but at a very high concentration, under which condition the blocker is known to also inhibit NAT, and it shows sensitivity to selective NAT blockers. Furthermore, the addition of the DAT blocker did not affect the activity beyond the blockade achieved with the NAT inhibitor alone. Given our current findings, we conclude that the DAT activity detected in these previous studies in finches was due to the expression of NAT in DA cells (Fig. 5b). Thus, our data provide a genetic basis for a characteristic feature of the DA re-uptake activity seen in a species that lacks a DAT gene. Of note, mammalian NAT has previously been shown to be capable of DA re-uptake, in fact even more so than DAT itself, and is thought to be responsible for synaptic DA re-uptake in mammalian cortical regions that receive noradrenergic innervation. Thus there is precedence for NAT playing a role in DA regulation, but this has never been reported as occurring through the expression of NAT in DA cells. Importantly, the avian NAT sequences are largely conserved with those in fish and mammals (Supplementary Fig. 7), and share higher amino acid identities with all orthologs of NAT compared to those of DAT (Supplementary Fig. 8). Moreover, the region of the chicken NAT protein that is predicted to encode all 12 transmembrane domains and extracellular loops (Supplemental Fig. 7) shares 98.8%, 90.7%, and 90.5% amino acid identity and 99.2%, 94.5%, and 94.5% amino acid similarity with orthologs in zebra finch, mouse, and human. In contrast, chicken NAT shares only 71.6% identity, and 83.1% similarity with human DAT. Furthermore, nearly every amino acid residue that has been linked to DA re-uptake activity based on analyses of site-directed mutations and chimeras is not only conserved in mammalian DAT orthologs, but also in both mammalian and avian NAT orthologs. Thus, like mammalian NAT, sauropsid NAT would be predicted to be capable of the re-uptake of both NA and DA.

Our study also provides insights into the phylogenetic origin of the DAT gene loss and of its apparent compensation via NAT. Both the NAT and DAT genes are clearly present in mammals and in outgroups to the amniotes, including amphibians and fish. They derive from an ancestral vertebrate duplication of an invertebrate monoamine transporter gene (MAT) with broad substrate specificity, which likely explains their shared ability to transport NA and DA. A previous study reporting a failure to clone a DAT brain transcript in a teleost, the medaka, had suggested that the gene might be missing in that species, but the study was conducted before the medaka genome was available. It is now clear that the DAT gene is present in medaka as well. In contrast, we found that the DAT gene, which is present in mammals, is absent in all sauropsids analyzed (including lizard, turtle, snake, crocodile, and birds).
most parsimonious explanation for this absence is the loss of the DAT gene in an ancestral sauropsid. While it is unclear how this loss occurred, it does not appear to have resulted from a major chromosomal rearrangement, since the local syntenic regions that flank the DAT gene are conserved across phylogeny, from fish to humans and, except for the missing DAT gene, also in sauropsids. Also interestingly, this region does not seem to be particularly enriched in repetitive elements. For instance, we find only one Long interspersed nuclear element (LINE) and one Long terminal repeat element (LTR) within the 15 kb region that should contain the DAT gene (not shown). Importantly, the expression of NAT in DA cells is unique to sauropsids, since the expression of NAT and DAT in both mammals and fish is segregated into NA and DA cells, respectively (our present data, which are consistent with a lack of NAT expression in DA cells in medaka45). These findings indicate that the segregated expression of these transporters is a basal condition in vertebrates, whereas the expression of NAT in DA cells is a uniquely sauropsid trait.

Our findings raise several questions about gene expression regulation in DA cells, most intriguingly how the modified expression of the NAT gene is accomplished in sauropsids. One possibility is that the regulatory region of NAT differs between birds/reptiles vs. mammals, accounting for the divergent expression modes. Under this scenario, the NAT promoter in sauropsids would contain cis-regulatory elements characteristic of mammalian DAT, which would allow for the regulated expression of NAT in DA cells. We found that the avian NAT promoter region resembles closely the mammalian NAT promoter, including the shared presence of a core proximal homeodomain-binding motif known to confer cell type-specific transcriptional regulation of human NAT through interactions with the transcription factors HOXA5 and PHOX2A46. However, we also found that avian NAT shares with mammalian DAT a few motifs that are absent in mammalian NAT. Among these, MZF1 and NFATC have previously been linked to regulation of phenotypic features of dopaminergic cells56,57. Thus, while the evidence does not broadly support a close similarity between the sauropsid NAT and mammalian DAT promoters, it points to some interesting candidate elements worth of further study. We also note that other DAT-related regulatory elements such as enhancers56,59 could be located upstream of the NAT promoter in sauropsids, and thus confer NAT expression in DA cells of this lineage. Alternatively, the key to cell-specific regulation might lie in DA cells in sauropsids (and not in mammals) expressing TFs (e.g. PHOX2A) that allow for NAT expression in DA cells39. Further analyses aimed at distinguishing among these possibilities should considerably deepen our understanding of factors that are critical for regulating gene expression in DA cells of vertebrates.

Our current findings also raise questions about whether other molecular and functional features of dopaminergic systems are conserved or not when comparing mammals vs. reptiles/birds. This is an important issue, given that DA and associated mechanisms are thought to play broad roles in basic functions such as the learning and execution of complex motor sequences and the expression of reward-seeking behaviors. Given the evidence for compensatory NAT expression in DA cells, it appears that DA uptake function is largely conserved in sauropsid and mammals. Of note, both DAT and NAT are major targets of cocaine and methamphetamine15,60,61. Since the NAT sequence in birds and reptiles is conserved with mammals, one would predict that despite the absence of the DAT gene, sauropsids would also be susceptible to these drugs if exposed to them. To our knowledge this possibility has not been tested, even though birds are useful experimental models for other drugs of abuse (e.g. 62–65). Lastly, the mechanisms underlying vocal learning and production have been widely studied in avian species, particularly songbirds. The extent to which the modulatory actions of dopaminergic circuits onto vocal acquisition and production pathways might be affected by the differences we have uncovered remains to be determined in future studies.

References
1. Wise, R. A. Dopamine, learning and motivation. Nat Rev Neurosci 5, 483–494; doi: 10.1038/nrn1406 (2004).
2. Berridge, K. C. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191, 391–431; doi: 10.1007/s00213-006-0578-x (2007).
3. Puig, M. V., Rose, J., Schmidt, R. & Freund, N. Dopamine modulation of learning and memory in the prefrontal cortex: insights from studies in primates, rodents, and birds. Frontiers in neural circuits 8, 93; doi: 10.3389/fncir.2014.00093 (2014).
4. Da Cunha, C., Gomez, A. A. & Blaha, C. D. The role of the basal ganglia in motivated behavior. Reviews in the neurosciences 23, 747–767; doi: 10.1515/revneuro-2012-0063 (2012).
5. Wickens, J. R., Reynolds, J. N. & Hyland, B. I. Neural mechanisms of reward-related motor learning. Curr Opin Neurobiol 13, 685–690 (2003).
6. Roepfer, J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci 36, 336–342; doi: 10.1016/j.tins.2013.03.003 (2013).
7. Medina, L. & Reiner, A. Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Brain Behav Evol 46, 235–258 (1995).
8. O’Connell, L. A., Fontenot, M. R. & Hofmann, H. A. Characterization of the dopaminergic system in the brain of an African cichlid fish, Astatotilapia burtoni. J Comp Neurol 519, 75–92; doi: 10.1002/cne.22256 (2011).
9. Meek, J., Joosten, H. W. & Steinbusch, H. W. Distribution of dopamine immunoreactivity in the brain of the mormyrid teleost Gnathonemus petersii. J Comp Neurol 281, 362–383; doi: 10.1002/cne.902810304 (1989).
10. Ekstrom, P., Reschke, M., Steinbusch, H. & van Veen, T. Distribution of noradrenaline in the brain of the teleost Gasterosteus aculeatus L.: an immunohistochemical analysis. J Comp Neurol 254, 297–313; doi: 10.1002/cne.902540304 (1986).
11. Smeets, W. J., Hoogland, P. V. & Voorn, P. The distribution of dopamine immunoreactivity in the forebrain and midbrain of the lizard Gekko gecko: an immunohistochemical study with antibodies against dopamine. J Comp Neurol 253, 46–60; doi: 10.1002/ cne.902530105 (1986).
12. Smeets, W. J. & Steinbusch, H. W. Distribution of noradrenaline immunoreactivity in the forebrain and midbrain of the lizard Gekko gecko. J Comp Neurol 285, 453–466; doi: 10.1002/cne.902850404 (1989).
13. Smets, W. J. A. J. & Reiner, A. Phylogeny and development of catecholamine systems in the CNS of vertebrates. (Cambridge University Press, 1994).

14. Kurian, M. A., Gissen, P., Smith, M., Heales, S., Jr. & Clayton, P. T. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. The Lancet. Neurology 10, 721–733; doi: 10.1016/S1474-4422(11)70141-7 (2011).

15. Zahniser, N. R. & Sorkin, A. Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47, Suppl 1, 80–91; doi: 10.1016/0027-9027(95)90083-7 (2004).

16. Vaughan, R. A. & Foster, J. D. Mechanisms of dopamine transporter regulation in normal and disease states. Trends in pharmacological sciences 34, 489–496; doi: 10.1016/j.tips.2013.07.005 (2013).

17. Balthazart, J., Baillien, M. & Ball, G. F. Interactions between aromatase (estrogen synthase) and dopamine in the control of male sexual behavior in quail. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 132, 37–55 (2002).

18. Charlier, T. D., Ball, G. F. & Balthazart, J. Sexual behavior activates the expression of the immediate early genes c-fos and Zenk (egr-1) in catecholaminergic neurons of male Japanese quail. Neuroscience 131, 13–30; doi: 10.1016/j.neuroscience.2004.09.068 (2005).

19. Leblois, A. Social modulation of learned behavior by dopamine in the basa ganglia: insights from songbirds. Journal of physiology, Paris 107, 219–229; doi: 10.1016/j.physparis.2012.09.002 (2013).

20. Riter, L. V. The role of motivation and reward neural systems in vocal communication in songbirds. Frontiers in neuroendocrinology 33, 194–209; doi: 10.1016/j.yfnef.2012.04.012 (2012).

21. Woolley, S. C., Sakata, J. T., Gupta, A. & Crews, D. Evolutionary changes in dopaminergic modulation of courtship behavior in the Portuguese whiptail lizard. Horm Behav 40, 483–489; doi: 10.1016/S0018-5042(01)00171-3 (2001).

22. Caveney, S., Cladman, W., Verellen, L. & Donly, C. Ancestry of neuronal monoamine transporters in the Metazoa. The Journal of experimental biology 209, 4858–4868; doi: 10.1242/jeb.02607 (2006).

23. Yamamoto, K. & Vernier, P. The evolution of dopamine systems in chordates. Frontiers in neuroanatomy 5, 21; doi: 10.3389/fnana.2011.00021 (2011).

24. Gale, S. D. & Perkel, D. J. Properties of dopamine release and uptake in the songbird basal ganglia. J Neurophysiol 93, 1871–1879; doi: 10.1152/jn.00477.2005 (2005).

25. Sasaki, A., Sotnikova, T. D., Gainetdinov, R. R. & Jarvis, E. D. Social context-dependent singing-regulated dopamine. J Neurosci 26, 9010–9014; doi: 26/35/9010/JNEUROSCI.1335-06.2006 (2006).

26. Kent, W. J. BLAT—the BLAST-like alignment tool. Genome research 12, 656–666; doi: 10.1101/gr.229202. (2002).

27. Zhang, G. et al. Comparative genomics reveals insights into avian genome evolution and adaptation. Science 346, 1311–1320; doi: 10.1126/science.1253185 (2014).

28. Wirthlin, M., Lovell, P. V., Jarvis, E. D. & Mello, C. V. Comparative genomics reveals molecular features unique to the songbird lineage. BMC Genomics 15, 1082; doi: 10.1186/1471-2164-15-1082 (2014).

29. Lovell, P. V. et al. Conserved syntenic clusters of protein coding genes are missing in birds. Genome Biol 15, 565; doi: 10.1186/s13059-014-0565-1 (2014).

30. Lovell, P. V., Carleton, J. B. & Mello, C. V. Genomics analysis of potassium channel genes in songbirds reveals molecular specializations of brain circuits for the maintenance and production of learned vocalizations. BMC Genomics 14, 470; doi: 10.1186/1471-2164-14-470 (2013).

31. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 4673–4680 (1994).

32. Karten, H. J. et al. Digital atlas of the zebra finch (taeniopygia guttata) brain: A high resolution photo atlas. J Comp Neuroiol; doi: 10.1002/cne.23443 (2013).

33. Lovell, P. V. & Mello, C. V. Brain expression and song regulation of cholecystokinin gene in the zebra finch (Taeniopygia guttata). J Comp Neuroiol in press (2011).

34. Reepledge, K. L. et al. The Songbird Neurogenomics (SoNG) Initiative: community-based tools and strategies for study of brain gene function and evolution. BMC Genomics 9, 131 (2008).

35. Lee, B. Y. et al. An EST resource for tilapia based on 17 normalized libraries and assembly of 116,899 sequence tags. BMC Genomics 11, 278; doi: 10.1186/1471-2164-11-278 (2010).

36. Alford, J. et al. The genome of the green anole lizard and a comparative analysis with birds and mammals. Nature 477, 587–591; doi: 10.1038/nature10390 (2011).

37. Carleton, J. B. et al. An Optimized Protocol for High-Throughput In Situ Hybridization of Zebra Finch Brain. Cold Spring Harb Protoc; doi: 10.1101/pdb.prot084582 (2014).

38. Lein, E. S. et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168–176; doi: nature05433/ nature05433 (2007).

39. Nixdorf-Bergweiler B. E. & Bischof, H.-J. A stereotaxic atlas of the brain of the zebra finch, Taeniopygia guttata, with special emphasis on telencephalic visual and song system nuclei in transversal and sagittal sections. National Library of Medicine, National Center for Biotechnology Information (2007).

40. Meek, J. in Phylogeny and Development of Catecholamine Systems in the CNS of Vertebrates. (eds Smets, W.I.A.J. & Reiner A.) 49–76 (Cambridge University Press, 1994).

41. Solovyev, V. V., Shakhmuratov, I. A. & Salamov, A. A. Identification of promoter regions and regulatory sites. Methods Mol Biol 674, 57–83; doi: 10.1007/978-1-60761-854-5_5 (2010).

42. Mathelier, A. et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res 42, D142–147; doi: 10.1093/nar/gkx997 (2014).

43. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nature reviews. Genetics 5, 276–287; doi: 10.1038/nrg1315 (2004).

44. Jarvis, E. D. et al. Whole-genome analyses resolve early branches in the tree of life of modern birds. Science 346, 1320–1331; doi: 10.1126/science.1253451 (2014).

45. Roubert, C. et al. A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Molecular pharmacology 60, 462–473 (2001).

46. Kim, H. S., Seo, H., Yang, C., Brunet, J. F. & Kim, K. S. Noradrenergic-specific transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2a-binding sites. J Neuroscience 18, 8247–8260 (1998).

47. Person, A. L., Gale, S. D., Farries, M. A. & Perkel, D. J. Organization of the songbird basal ganglia, including area X. J Comp Neurol 508, 840–866; doi: 10.1002/cne.21699 (2008).

48. Horn, A. S. Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopamine neurones in rat brain homogenates. Br J Pharmacol 47, 332–338 (1973).

49. Ehlilman, A. J. et al. Characteristics of drug interactions with recombiant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289, 877–885 (1999).
50. Giros, B. et al. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269, 15985–15988 (1994).
51. Gu, H., Wall, S. C. & Rudnick, G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269, 7124–7130 (1994).
52. Moron, J. A., Brockington, A., Wise, R. A., Rocha, B. A. & Hope, B. T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22, 389–395 (2002).
53. Uhl, G. R. & Lin, Z. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 479, 71–82 (2003).
54. Chen, N. & Reith, M. E. Structure and function of the dopamine transporter. Eur J Pharmacol 405, 329–339 (2000).
55. Norregaard, L. & Gether, U. The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating. Current opinion in drug discovery & development 4, 591–601 (2001).
56. Kosior, M., Zylinska, L., Zablocki, K. & Pikula, S. Calcineurin/NFAT signaling represses genes Vamp1 and Vamp2 via PMCA-dependent mechanism during dopamine secretion by Pheochromocytoma cells. PLoS One 9, e92176; doi: 10.1371/journal.pone.0092176 (2014).
57. Luo, X., Zhang, X., Shao, W., Yin, Y. & Zhou, J. Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures. J Neurochem 108, 952–961; doi: 10.1111/j.1471-4159.2008.05845.x (2009).
58. Donovan, D. M. et al. Human and mouse dopamine transporter genes: conservation of 5'-flanking sequence elements and gene structures. Brain research. Molecular brain research 30, 327–335 (1995).
59. Kim, C. H., Hwang, D. Y., Park, J. J. & Kim, K. S. A proximal promoter domain containing a homeodomain-binding core motif interacts with multiple transcription factors, including HoxA5 and Phox2 proteins, and critically regulates cell type-specific transcription of the human norepinephrine transporter gene. J Neurosci 22, 2579–2589; doi: 20026248 (2002).
60. Wei, H., Hill, E. R. & Gu, H. H. Functional mutations in mouse norepinephrine transporter reduce sensitivity to cocaine inhibition. Neuropharmacology 56, 399–404; doi: 10.1016/j.neuropharm.2008.09.008 (2009).
61. Han, D. D. & Gu, H. H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC pharmacology 6, 6; doi: 10.1186/1471-2210-6-6 (2006).
62. Olson, C. R., Owen, D. C., Ryabinin, A. E. & Mello, C. V. Drinking songs: alcohol effects on learned song of zebra finches. PLoS One 9, e115427; doi: 10.1371/journal.pone.0115427 (2014).
63. Levens, N. & Akins, C. K. Cocaine induces conditioned place preference and increases locomotor activity in male Japanese quail. Pharmacology, biochemistry, and behavior 68, 71–80 (2001).
64. Lemmonds, C. A., Williams, D. K. & Wenger, G. R. Effect of pentobarbital, d-amphetamine, and nicotine on two models of inhibition. J Neurochem 71–82 (2003).
65. Walker, E. A., Picker, M. J., Granger, A. & Dykstra, L. A. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther 310, 150–158; doi: 10.1124/jpet.103.085803 (2004).

Acknowledgements

We thank M. Wirthlin for helpful comments and editing of the manuscript, T. Marzula for assistance with zebra finch in situ hybridizations, Amy Eshleman (OHSU) for useful insights into DAT pharmacology and comments on the text, the Mitra lab (Cold Spring Harbor) for performing the high-resolution scanning of in situ patterns, J. Colbourne (University of Liverpool) and S. Michaels for providing the Green anole cDNAs, the Kocher lab (Univ. Maryland) and Cichlid Genome Consortium for providing the Oreochromis niloticus clones, and Suzy Renn (Reed College) for generously providing brains of the Astatotilapia burtoni. This study was funded by the NIH through a resource grant from the NIGMS (R24-GM092842) to CVM.

Author Contributions

Conceived and designed the experiments: P.V.L. and C.V.M. Performed the experiments: J.B.C., B.K. and Astatotilapia burtoni clones, and Suzy Renn (Reed College) for generously providing brains of the Astatotilapia burtoni. This study was funded by the NIH through a resource grant from the NIGMS (R24-GM092842) to CVM.

Author Contributions

Conceived and designed the experiments: P.V.L. and C.V.M. Performed the experiments: J.B.C., B.K. and P.V.L. Cloned Zebra finch dopamine beta-hydroxylase template: T.A.V. Analyzed the data and wrote the paper: P.V.L. and C.V.M. All of the authors have read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Lovell, P. V. et al. Living without DAT: Loss and compensation of the dopamine transporter gene in sauropsids (birds and reptiles). Sci. Rep. 5, 14093; doi: 10.1038/srep14093 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/